The popularity of copyright’s blockbuster initially sparked a boom for pharma, but recent shifts present a uncertain scenario for investors. Off-patent alternatives are eroding revenue, and continued litigation add https://maeilrb538879.wssblogs.com/41083342/the-blue-pill-and-the-pharmaceutical-industry-a-volatile-investment